

# An evaluation of a brief assessment-led intervention with young non-injecting drug users

<b>Submission date</b> 13/02/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 26/02/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 06/08/2020	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr John Marsden

### Contact details

Institute of Psychiatry  
King's College London  
PO Box 048  
4 Windsor Walk  
London  
United Kingdom  
SE5 8AF

-

J.Marsden@iop.kcl.ac.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

V#1, 10/01/06

# Study information

## Scientific Title

An evaluation of a brief assessment-led intervention with young non-injecting drug users

## Study objectives

That participants receiving a brief assessment-led intervention would at 3 months follow-up have a lower mean frequency of cannabis use, cocaine use, crack cocaine use and MDMA (3,4 methylenedioxymethamphetamine; Ecstasy) use combined than delayed assessment control participants

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

King's College London, 17/10/2005, ref: 05/Q0706/219

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Prevention

## Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

## Health condition(s) or problem(s) studied

Substance misuse

## Interventions

Experimental: A brief assessment-led intervention

a. Drugs and Lifestyle Assessment

b. Manual guided 30 minute feedback interview

Control 1: Assessment only

Control 2: Delayed assessment

## Intervention Type

## Behavioural

### Primary outcome measure

Combined frequency of cocaine powder use, crack cocaine use, MDMA use and cannabis use, assessed at baseline and 90 days

### Secondary outcome measures

The following were assessed at baseline and 90 days:

1. Typical intensity of cannabis use, cocaine use, crack cocaine use and MDMA use at 90 days
2. Drug dependency: Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) Personality Disorders (Structured Clinical Interview for DSM-IV Axis II Personality Disorders; SCID-II)
3. Alcohol frequency and intensity
4. Hazardous drinking: The Alcohol Use Disorders Identification Test (AUDIT)
5. General health: EQ-5D A multi-dimensional Quality of Health Instrument (EurQol)
6. Psychological health: General Health Questionnaire (GHQ 12)
7. Engagement with health and social services

### Overall study start date

01/10/2005

### Completion date

29/01/2008

## Eligibility

### Key inclusion criteria

1. 16 to 28 years old
2. Using either cannabis, cocaine powder, crack cocaine, or MDMA on four days in previous month
3. Able speak and comprehend English
4. Written consent

### Participant type(s)

Other

### Age group

Adult

### Sex

Both

### Target number of participants

255

### Total final enrolment

342

### Key exclusion criteria

1. In contact with a drug/alcohol treatment agency in previous 12 months
2. Used opiates more than 30 days in the previous 90 days or in the previous 48 hours before

interview

3. Injected more than once in the last 12 months and no more than ten times lifetime

4. Receiving specialist treatment for a mental health problem

5. Participated in a similar research study in the previous 12 months

**Date of first enrolment**

01/10/2005

**Date of final enrolment**

29/01/2008

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Institute of Psychiatry**

London

United Kingdom

SE5 8AF

## **Sponsor information**

**Organisation**

King's College London (UK)

**Sponsor details**

Institute of Psychiatry

Kings College London

4 Windsor Walk

London

England

United Kingdom

SE5 8AF

-

[gill.lambert@iop.kcl.ac.uk](mailto:gill.lambert@iop.kcl.ac.uk)

**Sponsor type**

University/education

**Website**

<http://www.iop.kcl.ac.uk>

ROR

<https://ror.org/0220mzb33>

## Funder(s)

### Funder type

Government

### Funder Name

Department of Health of England & Wales, Drug Misuse Research Initiative (Phase 2) (UK)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/07/2006	06/08/2020	Yes	No